BGV wraps up fourth fund
BioGeneration Ventures, an early-stage venture firm focused on European biopharma, has closed its fourth fund at $119 million.
BioGeneration Ventures, an early-stage venture firm focused on European biopharma, has closed its fourth fund at $119 million.
Copyright PEI Media
Not for publication, email or dissemination